Yesterday positive results from phase 2 study of their oral vaccine against flu was released. Seeking alpha: The vaccine elicited a significant expansion of mucosal homing receptor alfa4beta7+ (beta7+) plasmablasts, cells that play a key role in an immune response, to about 60% of all activated B cells, significantly higher than 20% from Sanofi's (NYSE:SNY) Fluzone.
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.